Efficacy Study of Oral Collagen Peptide on Skin Condition Improvement
Efficacy Study of Oral Collagen Peptide on Skin Conditions
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 021
- Shanghai Fumei Dermatology Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy female adults aged between 35-55 years old
- With fine wrinkles and skin laxity
- Personal informed consents to participate in the study
- Agree to keep their daily skincare routine unchanged for the duration of the study
- Maintain good sun protection habits
5. Agree to refrain from wearing make-up on the face on the each study visit
Exclusion Criteria
- Female who is pregnant or nursing or planning to become pregnant during the course of the study
- Individuals who are in the perimenopausal stage.
- BMI<18.5 or BMI >27.9
- Individuals suffering from chronic systemic diseases such as cardiovascular, cerebrovascular, liver, and kidney diseases.
- Individuals who have diabetes.
- Individuals suffering from skin conditions such as psoriasis, eczema, atopic dermatitis, and severe acne.
- Individuals with depression or sleep disorders, those who smoke, and those who abuse alcohol.
- Individuals who are using hormonal drugs, medications for obesity, absorption inhibitors, antidepressants, or appetite suppressants.
- Individuals who have used hormones or anti-inflammatory drugs on their face and upper arms within the past two months.
- Individuals who received facial laser therapy, chemical peeling or UV overexposure in the past 3 months
- Individuals who can not avoid prolonged exposure to sunlight.
- Individuals who are currently participating in other clinical studies or trials.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Active Comparator
collagen peptide solid beverage
|
LISAVEI collagen peptide solid beverage ( contain 5 g collagen peptide),once daily for 12 weeks
|
|
Placebo Comparator: Placebo Comaprator
placebo solid beverage
|
placebo solid beverage (Maltodextrin with edible flavor),once daily for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Skin firmness
Time Frame: before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)
|
The changes of skin firmness parameter tested by Cutometer MPA580
|
before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)
|
|
Skin thickness
Time Frame: before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)
|
The changes of skin thickness (μm) tested by Ultrascan UC 22
|
before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)
|
|
Skin density
Time Frame: before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)
|
The changes of skin density tested by Ultrascan UC 22
|
before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Skin hydration
Time Frame: before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)
|
The changes of skin hydration tested by Corneometer CM825
|
before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)
|
|
Skin barrier
Time Frame: before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)
|
The changes of Trans Epidermal Water Loss (skin barrier parameter) tested by Tewameter TM300
|
before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)
|
|
Facial image
Time Frame: before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)
|
Photo documents of left, right and frontal facial views
|
before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- YKEC-2024-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.